Array Biopharma company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

arraybiopharma.com

Founded Year

1998

Stage

Acq - P2P | Acquired

Total Raised

$32.81M

Valuation

$0000 

About Array Biopharma

Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. The company is building a fully integrated, commercial-stage biopharmaceutical company that discovers, develops and markets safe and effective small molecule drugs to treat patients afflicted with cancer.

Array Biopharma Headquarter Location

3200 Walnut Street

Boulder, Colorado, 80301,

United States

303-381-6600

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Array Biopharma

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Array Biopharma in 2 CB Insights research briefs, most recently on Sep 18, 2019.

Expert Collections containing Array Biopharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Array Biopharma is included in 2 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

838 items

Array Biopharma Patents

Array Biopharma has filed 225 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Experimental cancer drugs
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/14/2020

3/8/2022

Experimental cancer drugs, Monoclonal antibodies, Fluoroarenes, Analgesics, Transcription factors

Grant

Application Date

9/14/2020

Grant Date

3/8/2022

Title

Related Topics

Experimental cancer drugs, Monoclonal antibodies, Fluoroarenes, Analgesics, Transcription factors

Status

Grant

Latest Array Biopharma News

Gastric Cancer Drugs Global Market Report 2022

Mar 16, 2022

" - https://www.reportlinker.com/p06245006/?utm_source=GNW , AstraZeneca, Bayer Healthcare, Abbott, AROG Pharmaceuticals, Ipsen Biopharmaceuticals, Array Biopharma, Taiho Oncology, AstraZeneca, ARIAD Pharmaceuticals, Ono Pharmaceutical, Jiangsu HengRui Medicine, Gilead Bioscience, Celgene/Taiho, Boston Biomedical, Imugene Limited, Boehringer Ingelheim, Daiichi-Sankyo and Danaher corporation. The global gastric cancer drugs market is expected to grow from $2.63 billion in 2021 to $3.05 billion in 2022 at a compound annual growth rate (CAGR) of 15.9%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $5.18 billion in 2025 at a CAGR of 14.2%. The gastric cancer drugs market consists of sales of drugs for gastric cancer. Gastric cancer, also known as stomach cancer, is the formation of abnormal cells on the lining of stomach resulting in stomach pain and indigestion. The main types of gastric cancer drugs are doxorubicin hydrochloride, sunitinib, docetaxel, mitomycin, fluorouracil, imatinib and trastuzumab. Sunitinib is a chemotherapeutic agent and receptor tyrosine kinase inhibitor used to treat renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumour (GIST). The drugs are administered through oral and parenteral that are used by hospitals, clinics, and others North America was the largest region in the gastric cancer drugs market in 2021.Middle East is expected to be the fargest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. Increasing number of obesity cases and smoking population increased number of people suffering from gastric cancer.Consuming tobacco and following diet unhealthy diet increases the risk of stomach cancer. According to the estimates of American Institute for Cancer Research for 2020, about 27,600 cases of stomach cancer will be diagnosed (16,980 in men and 10,620 in women). Increase in number of cases in gastric cancer will drive the market for gastric cancer drugs. Stringent regulations and policies for approval of the drugs restrain the market for gastric cancer drugs.Different regions have their own set of rules, guidelines and regulations set by their respective drugs regulation board. For example, the USFDA regulations for American pharmaceuticals states various conditions with regards to safety and effectiveness of the drug as well as certain labeling requirements.Similarly, the European medicines agency (EMA) gives licenses to the approved drugs before they can be marketed or commercialized in the European continent. Teysuno, a drug for advanced gastric cancer can be only obtained through a valid prescription and the protocol is that every company must assess the effects of using Teysuno and must list out the precautions to be taken by patients and healthcare providers to minimize any possible side effects. These regulations hinder the growth of the gastric cancer drugs market. Many companies are using combination therapies to cure gastric cancer.Combination therapies help in treating patients with two or more drugs for a single disease and help in better treating the patients. For instance, in 2019, the USFDA has approved Taiho Oncology Inc’s combined product LONSURF trifluridine/tipiracil for pre-treated metastatic gastric cancer. This approval is significant for patients living with advanced gastric or GEJ (gastroesophageal junction) adenocarcinoma who have limited effective treatment options after failure of standard treatment options. Advances in the drugs for treatment of gastric cancer will have a positive influence on the gastric cancer drugs’ market The gastric cancer drugs market is regulated by government agencies such as European Medicines Agency (EMA), USFDA (the US food and drug ministration), and others.For instance, FDA’s Current Good Manufacturing Practice (CGMP) regulation lays down minimum requirements for the methods and facilities used in manufacturing, processing, and packing of a drug product and ensures the quality of drugs produced by manufacturers. Moreover, FDA’s guidance provides recommendations to applicants for cancer clinical trials and shows support in new drug applications (NDAs), biologics license applications (BLAs), or supplemental applications. On April 2019, AstraZeneca, a multinational pharmaceutical and biopharmaceutical company acquired Daiichi Sankyo for $1.35 billion. This acquisition will help AstraZeneca to jointly develop drug Trastuzumab Deruxtecan with Daiichi Sankyo. This drug would help to treat people suffering from breast and gastric cancer. Daiichi Sankyo headquarted at Japan is a global pharmaceutical company which offers innovative products and a robust pipeline for cancer treatment. The countries covered in the gastric cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

  • When was Array Biopharma founded?

    Array Biopharma was founded in 1998.

  • Where is Array Biopharma's headquarters?

    Array Biopharma's headquarters is located at 3200 Walnut Street, Boulder.

  • What is Array Biopharma's latest funding round?

    Array Biopharma's latest funding round is Acq - P2P.

  • How much did Array Biopharma raise?

    Array Biopharma raised a total of $32.81M.

  • Who are the investors of Array Biopharma?

    Investors of Array Biopharma include Pfizer, Advent International, ARCH Venture Partners, Boulder Ventures, Falcon Technology Venture Partners and 6 more.

  • Who are Array Biopharma's competitors?

    Competitors of Array Biopharma include Cerecin, Clarus Therapeutics, MaxCyte, Oxurion, Pfenex, Molmed, Portola Pharmaceuticals, AM-Pharma, Trellis Bioscience, Achillion Pharmaceuticals and 85 more.

You May Also Like

Oligomerix Logo
Oligomerix

Oligomerix is a biopharmaceutical company focused on development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers and their newly discovered proteolytic enzymatic activity. The Company was founded in 2006 and is located within the Audubon Biomedical Science and Technology Park at Columbia University Medical Center.

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

Cerecin Logo
Cerecin

Cerecin is a biopharmaceutical company with a drug for Alzheimer's in late-stage clinical testing. Cerecin's pipeline consists of therapeutic drugs and medical foods for neurodegenerative diseases such as Alzheimer's, Parkinson's, and Age-Associated Memory Impairment.

B
Bikam Pharmaceuticals

BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.

REGiMMUNE Logo
REGiMMUNE

REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat conditions such as allergies, autoimmune diseases and inflammatory disorders.

L
Limerick BioPharma

Limerick BioPharma is developing compounds that per the company when used adjunctively with both marketed and investigational drugs improve drug side effect profiles and clinical outcomes. By activating cellular transport pumps to redistribute drugs away from organs and tissues where they have adverse effects, the company's compounds aim to minimize toxic side effects at non-targeted vulnerable organs and tissues while maintaining or enhancing a drug's desired effects. Per the company, Limerick's pipeline molecules are applicable to a broad range of therapeutic drug classes including immunosuppressants, opioids, immunomodulators, selective estrogens receptor modulators, and psychotropics. In the monotherapy setting, Limerick is developing novel compounds that target the treatment of metabolic diseases such as hypercholesteremia and hyperglycemia via a mechanism related to reverse cholesterol transport.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.